Abstract
Fowlpox virus (FPV) is a double-stranded DNA virus with a history of use as a live attenuated vaccine in commercial poultry production systems. FPV is also highly amenable to genetic engineering, with a large cloning capacity and many nonessential sites available for integration, meaning that in recombinant form, several transgenes can be expressed simultaneously. Recombinant FPV has proven an effective prophylactic vaccine vector for other diseases of birds, as well as other animal species (Brun et al., Vaccine 26:6508–6528, 2008). These vectors do not integrate into the host genome nor do they undergo productive replication in mammalian cells; thus they have a proven and impeccable safety profile and have been progressed as prophylactic and therapeutic vaccine vectors for use in humans (Beukema et al., Expert Rev Vaccines 5:565–577, 2006; Lousberg et al., Expert Rev Vaccines 10:1435–1449, 2011). Furthermore, repeated immunization with FPV does not blunt subsequent vaccine responses, presumably because it is replication-defective, and thus larger doses can be routinely administered (Brun et al., Vaccine 26:6508–6528, 2008). This strengthens the case for FPV as a viable platform vaccine vector, as it means it can be used repeatedly in an individual to achieve different immunological outcomes. Here we describe in detail the construction of a recombinant variant of FPV expressing the prostate tumor-associated antigen prostatic acid phosphatase (PAP) in conjunction with the immunostimulatory cytokine, interleukin-2 (IL-2), which, if undertaken under the appropriate regulatory conditions and with approvals in place, would theoretically be amenable to clinical trial applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Brun A et al (2008) Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems. Vaccine 26:6508–6528
Beukema EL et al (2006) The potential role of fowlpox virus in rational vaccine design. Expert Rev Vaccines 5:565–577
Lousberg EL et al (2011) Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines 10:1435–1449
Tulman ER et al (2004) The genome of canarypox virus. J Virol 78:353–366
Soboll G et al (2010) Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC®) vaccination. Vet Immunol Immunopathol 135:100–107
Seino KK et al (2007) Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin Vaccine Immunol 14:1465–1471
Larson LJ, Schultz RD (2007) Three-year duration of immunity in dogs vaccinated with a canarypox-vectored recombinant canine distemper virus vaccine. Vet Ther 8:101–106
Taylor J et al (1994) Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. Dev Biol Stand 82:131–135
Gilbert PB et al (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 21:2933–2947
Rerks-Ngarm S et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220
Gonczol E, Plotkin S (2001) Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1:401–412
Tartaglia J et al (2001) Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 19:2571–2575
Boyle DB, Coupar BE (1988) Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 10:343–356
Taylor J et al (1988) Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 6:504–508
Taylor J et al (1990) Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol 64:1441–1450
French MA et al (2010) Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a ‘high affinity’ FcγRIIa genotype. AIDS 24:1983–1990
Baxby D, Paoletti E (1992) Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10:8–9
Taylor J, Paoletti E (1988) Fowlpox virus as a vector in non-avian species. Vaccine 6:466–467
Beard CW et al (1991) Protection of chickens against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses. Avian Dis 35:356–359
Emery S et al (2007) Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin 3:260–267
Emery S et al (2005) Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects. Hum Vaccin 1:232–238
Falkner FG, Moss B (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64:3108–3111
Acknowledgment
J.D.H. is in receipt of research funding support from Sementis Ltd. P.M.H. is the Chief Scientific Officer, co-founder, and a major shareholder of Sementis Ltd. K.R.D. is supported by a training fellowship and grant from the National Health and Medical Research Council of Australia.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Howley, P.M., Diener, K.R., Hayball, J.D. (2014). Making an Avipoxvirus Encoding a Tumor-Associated Antigen and a Costimulatory Molecule. In: Lawman, M., Lawman, P. (eds) Cancer Vaccines. Methods in Molecular Biology, vol 1139. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0345-0_32
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0345-0_32
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0344-3
Online ISBN: 978-1-4939-0345-0
eBook Packages: Springer Protocols